To evaluate whether direct oral anticoagulant (DOAC) therapy in patients with device-detected atrial fibrillation (AF) is cost-effective from a health system perspective, particularly given the uncertainty surrounding its benefits.
Key Findings:
Anticoagulation modestly reduced the risk of stroke but increased the risk of major bleeding. The net benefit of anticoagulant therapy in terms of gained QALYs is minimal and uncertain. The study followed CHEERS reporting guidelines and used publicly available data, which supports its validity.
Interpretation:
The study indicates that while anticoagulation may provide some benefits, the cost-effectiveness remains uncertain, highlighting the need for careful consideration in clinical practice.
Limitations:
The model did not include nonintracranial bleeding events significantly impacting quality of life, which could affect the overall assessment. The analysis was based on a hypothetical patient population and may not fully represent real-world scenarios, suggesting caution in generalizing the findings.
Conclusion:
The cost-effectiveness of DOAC therapy in subclinical AF remains to be clearly established despite the potential for marginal clinical benefits, indicating a need for further research.
